SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03604211

Enrollment

Registered

2018-07-27

Start date

2010-01-31

Completion date

2018-07-31

Last updated

2018-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymph Node Metastases, Prostate Cancer, Prostate Cancer Recurrent

Brief summary

Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Detailed description

Single-institution retrospective analysis of consecutive prostate cancer patients after definitive primary treatment, without local recurrence, presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015. Endpoints of interest are biochemical response rate (defined as a reduction by at least 10% of the initial PSA value), time to biochemical recurrence (TBR) (defined as the time interval from SBRT until second PSA rise), and time interval between SBRT and ADT start. Univariate analysis is used to identify prognostic factors.

Interventions

RADIATIONCyberknife Radiation Therapy

Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 85 Years

Inclusion criteria

* histologically proven diagnosis of prostate cancer * Radical prostatectomy (± salvage radiotherapy) * PSA relapse (defined by two consecutive rising PSA values \>0.2 ug/l) * one to three lymphnodes positive on Choline-PET * no recurrence in prostatic bed on Choline-PET * WHO performance status of 0-1 * no previous chemotherapy or ADT for prostate cancer.

Exclusion criteria

* primary treatment for prostate cancer by RT or brachytherapy * bone (M1b) metastases * visceral (M1c) metastases * any symptomatic nodal lesion

Design outcomes

Primary

Measure	Time frame	Description
time to biochemical recurrence	18 months	time interval from SBRT until second PSA rise

Secondary

Measure	Time frame	Description
biochemical response rate	18 months	reduction by at least 10% of the initial PSA value
time interval between SBRT and ADT start	18 months	time interval between SBRT and ADT start

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026